AUS
NZ
UK
CA
USA
IND
Neuren Pharmaceuticals Ltd (ASX:NEU) has shared promising results from its Phase 2 clinical trial of NNZ-2591, a drug designed to treat Angelman syndrome, a rare genetic disorder affecting the nervous system. The trial, which involved children aged 3 to 17, aimed to assess the drug’s safety and effectiveness.
The results revealed significant improvements in key areas including communication, behavior, cognition, and motor skills. These improvements were measured using specialized tools for Angelman syndrome, with the Clinical Global Impression of Improvement (CGI-I) score showing a mean score of 3.0, indicating noticeable progress for most children. The Caregiver Overall Impression of Change (CIC) score also reflected meaningful positive changes.
NNZ-2591, administered orally as a liquid twice daily, was well tolerated, with no serious adverse effects reported. Despite these encouraging results, Neuren's stock experienced a 7% drop this morning. This reaction could be attributed to investor expectations for more dramatic results or clearer evidence of long-term benefits.
Avita Medical Ltd (ASX:AVH)
Avita Medical Ltd has announced strong Q2 financial results, with commercial revenue reaching $15.1 million, a 29% increase from the previous year. The gross profit margin stood at 86.2%. The company received FDA approval for its RECELL GO treatment, which addresses thermal burn wounds and full-thickness skin defects. The first use of this treatment has already been completed.
Avita Medical has also submitted an application for the RECELL GO mini, designed for smaller wounds, which is expected to be reviewed by the FDA due to its Breakthrough Device status. Approval for the RECELL GO mini is anticipated by December 2024, with ongoing study results expected by the end of the year.
For Q3, Avita forecasts revenue between $19 and $20 million, with full-year revenue projected between $68 and $70 million. The company is targeting profitability by the end of Q3 FY25.
IDT Australia Ltd (ASX:IDT)
IDT Australia Ltd has secured a new contract with Sanofi Australia valued between $2.5 million and $4 million. This contract covers preclinical work, including the formulation, development, and manufacturing of Sanofi’s messenger RNA (mRNA) technology for clinical trials.
This contract follows an earlier Master Service Agreement (MSA) with Sanofi, which allows for the selection of various services and the setup of additional projects.
These updates reflect significant developments for Neuren Pharmaceuticals, Avita Medical, and IDT Australia, highlighting advancements in clinical trials, financial growth, and strategic partnerships.
